Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 155

1.

Exploratory Study of Predicted Indirectly ReCognizable HLA Epitopes in Mismatched Hematopoietic Cell Transplantations.

Geneugelijk K, Thus KA, van Deutekom HWM, Calis JJA, Borst E, Keşmir C, Oudshoorn M, van der Holt B, Meijer E, Zeerleder S, de Groot MR, von dem Borne PA, Schaap N, Cornelissen J, Kuball J, Spierings E.

Front Immunol. 2019 Apr 24;10:880. doi: 10.3389/fimmu.2019.00880. eCollection 2019.

2.

Phase 2 study of carfilzomib, thalidomide, and low-dose dexamethasone as induction and consolidation in newly diagnosed, transplant eligible patients with multiple myeloma, the carthadex trial.

Wester R, van der Holt B, Asselbergs E, Zweegman S, Kersten MJ, Vellenga E, van Marwijk Kooy M, de Weerdt O, Minnema M, Lonergan S, Palumbo A, Lokhorst H, Broijl A, Sonneveld P.

Haematologica. 2019 Apr 4. pii: haematol.2018.205476. doi: 10.3324/haematol.2018.205476. [Epub ahead of print]

3.

Immunophenotypic measurable residual disease (MRD) in acute myeloid leukemia: Is multicentric MRD assessment feasible?

Brooimans RA, van der Velden VHJ, Boeckx N, Slomp J, Preijers F, Te Marvelde JG, Van NM, Heijs A, Huys E, van der Holt B, de Greef GE, Kelder A, Schuurhuis GJ.

Leuk Res. 2019 Jan;76:39-47. doi: 10.1016/j.leukres.2018.11.014. Epub 2018 Nov 27.

4.

The feasibility and efficacy of subcutaneous plerixafor for mobilization of peripheral blood stem cells in allogeneic HLA-identical sibling donors: results of the HOVON-107 study.

de Greef GE, Braakman E, van der Holt B, Janssen JJWM, Petersen E, Vucinic V, Thuss N, Grootes M, Cornelissen JJ.

Transfusion. 2019 Jan;59(1):316-324. doi: 10.1111/trf.15037. Epub 2018 Dec 11.

PMID:
30548284
5.

Protocol for the STRONG trial: stereotactic body radiation therapy following chemotherapy for unresectable perihilar cholangiocarcinoma, a phase I feasibility study.

Koedijk MS, Heijmen BJM, Groot Koerkamp B, Eskens FALM, Sprengers D, Poley JW, van Gent DC, van der Laan LJW, van der Holt B, Willemssen FEJA, Méndez Romero A.

BMJ Open. 2018 Oct 15;8(10):e020731. doi: 10.1136/bmjopen-2017-020731.

6.

Thalidomide before and after autologous stem cell transplantation in recently diagnosed multiple myeloma (HOVON-50): long-term results from the phase 3, randomised controlled trial.

van de Donk NW, van der Holt B, Minnema MC, Vellenga E, Croockewit S, Kersten MJ, von dem Borne PA, Ypma P, Schaafsma R, de Weerdt O, Klein SK, Delforge M, Levin MD, Bos GM, Jie KG, Sinnige H, Coenen JL, de Waal EG, Zweegman S, Sonneveld P, Lokhorst HM.

Lancet Haematol. 2018 Oct;5(10):e479-e492. doi: 10.1016/S2352-3026(18)30149-2.

PMID:
30290905
7.

Mesh versus suture repair of umbilical hernia in adults: a randomised, double-blind, controlled, multicentre trial.

Kaufmann R, Halm JA, Eker HH, Klitsie PJ, Nieuwenhuizen J, van Geldere D, Simons MP, van der Harst E, van 't Riet M, van der Holt B, Kleinrensink GJ, Jeekel J, Lange JF.

Lancet. 2018 Mar 3;391(10123):860-869. doi: 10.1016/S0140-6736(18)30298-8. Epub 2018 Feb 17.

PMID:
29459021
8.

Impaired thymopoiesis predicts for a high risk of severe infections after reduced intensity conditioning without anti-thymocyte globulin in double umbilical cord blood transplantation.

Duinhouwer LE, Beije N, van der Holt B, Rijken-Schelen A, Lamers CH, Somers J, Braakman E, Cornelissen JJ.

Bone Marrow Transplant. 2018 Jun;53(6):673-682. doi: 10.1038/s41409-018-0103-y. Epub 2018 Feb 9.

PMID:
29426829
9.

Autologous Dendritic Cells Pulsed with Allogeneic Tumor Cell Lysate in Mesothelioma: From Mouse to Human.

Aerts JGJV, de Goeje PL, Cornelissen R, Kaijen-Lambers MEH, Bezemer K, van der Leest CH, Mahaweni NM, Kunert A, Eskens FALM, Waasdorp C, Braakman E, van der Holt B, Vulto AG, Hendriks RW, Hegmans JPJJ, Hoogsteden HC.

Clin Cancer Res. 2018 Feb 15;24(4):766-776. doi: 10.1158/1078-0432.CCR-17-2522. Epub 2017 Dec 12.

10.

Bortezomib before and after high-dose therapy in myeloma: long-term results from the phase III HOVON-65/GMMG-HD4 trial.

Goldschmidt H, Lokhorst HM, Mai EK, van der Holt B, Blau IW, Zweegman S, Weisel KC, Vellenga E, Pfreundschuh M, Kersten MJ, Scheid C, Croockewit S, Raymakers R, Hose D, Potamianou A, Jauch A, Hillengass J, Stevens-Kroef M, Raab MS, Broijl A, Lindemann HW, Bos GMJ, Brossart P, van Marwijk Kooy M, Ypma P, Duehrsen U, Schaafsma RM, Bertsch U, Hielscher T, Jarari L, Salwender HJ, Sonneveld P.

Leukemia. 2018 Feb;32(2):383-390. doi: 10.1038/leu.2017.211. Epub 2017 Jul 4.

PMID:
28761118
11.

Consequences of Referral Time and Volume Doubling Time in Inoperable Patients With Early Stage Lung Cancer.

Frelinghuysen M, Fest J, Van der Voort Van Zyp NC, Van der Holt B, Hoogeman M, Nuyttens J.

Clin Lung Cancer. 2017 Nov;18(6):e403-e409. doi: 10.1016/j.cllc.2017.05.002. Epub 2017 May 10.

PMID:
28571689
12.

Lack of detectable platelet autoantibodies is correlated with nonresponsiveness to rituximab treatment in ITP patients.

Porcelijn L, Huiskes E, Schipperus M, van der Holt B, de Haas M, Zwaginga JJ; Dutch HOVON 64 Study Group.

Blood. 2017 Jun 22;129(25):3389-3391. doi: 10.1182/blood-2016-11-751719. Epub 2017 May 3. No abstract available.

13.

Comparison of 2D (RANO) and volumetric methods for assessment of recurrent glioblastoma treated with bevacizumab-a report from the BELOB trial.

Gahrmann R, van den Bent M, van der Holt B, Vernhout RM, Taal W, Vos M, de Groot JC, Beerepoot LV, Buter J, Flach ZH, Hanse M, Jasperse B, Smits M.

Neuro Oncol. 2017 Jun 1;19(6):853-861. doi: 10.1093/neuonc/now311.

14.

Ofatumumab Versus Rituximab Salvage Chemoimmunotherapy in Relapsed or Refractory Diffuse Large B-Cell Lymphoma: The ORCHARRD Study.

van Imhoff GW, McMillan A, Matasar MJ, Radford J, Ardeshna KM, Kuliczkowski K, Kim W, Hong X, Goerloev JS, Davies A, Barrigón MDC, Ogura M, Leppä S, Fennessy M, Liao Q, van der Holt B, Lisby S, Hagenbeek A.

J Clin Oncol. 2017 Feb 10;35(5):544-551. doi: 10.1200/JCO.2016.69.0198. Epub 2016 Dec 28.

PMID:
28029326
15.

Matching for the nonconventional MHC-I MICA gene significantly reduces the incidence of acute and chronic GVHD.

Carapito R, Jung N, Kwemou M, Untrau M, Michel S, Pichot A, Giacometti G, Macquin C, Ilias W, Morlon A, Kotova I, Apostolova P, Schmitt-Graeff A, Cesbron A, Gagne K, Oudshoorn M, van der Holt B, Labalette M, Spierings E, Picard C, Loiseau P, Tamouza R, Toubert A, Parissiadis A, Dubois V, Lafarge X, Maumy-Bertrand M, Bertrand F, Vago L, Ciceri F, Paillard C, Querol S, Sierra J, Fleischhauer K, Nagler A, Labopin M, Inoko H, von dem Borne PA, Kuball J, Ota M, Katsuyama Y, Michallet M, Lioure B, Peffault de Latour R, Blaise D, Cornelissen JJ, Yakoub-Agha I, Claas F, Moreau P, Milpied N, Charron D, Mohty M, Zeiser R, Socié G, Bahram S.

Blood. 2016 Oct 13;128(15):1979-1986. Epub 2016 Aug 22.

16.

Treatment of secondary central nervous system lymphoma with intrathecal rituximab, high-dose methotrexate, and R-DHAP followed by autologous stem cell transplantation: results of the HOVON 80 phase 2 study.

Doorduijn JK, van Imhoff GW, van der Holt B, Schouten HC, Schaafsma MR, MacKenzie MA, Baars JW, Kersten MJ, Lugtenburg PJ, van den Bent MJ, Enting RH, Spoelstra FM, Poortmans P, Bromberg JEC.

Hematol Oncol. 2017 Dec;35(4):497-503. doi: 10.1002/hon.2342. Epub 2016 Aug 17.

PMID:
27530779
17.

Influence of the Acidic Beverage Cola on the Absorption of Erlotinib in Patients With Non-Small-Cell Lung Cancer.

van Leeuwen RW, Peric R, Hussaarts KG, Kienhuis E, IJzerman NS, de Bruijn P, van der Leest C, Codrington H, Kloover JS, van der Holt B, Aerts JG, van Gelder T, Mathijssen RH.

J Clin Oncol. 2016 Apr 20;34(12):1309-14. doi: 10.1200/JCO.2015.65.2560. Epub 2016 Feb 8. Erratum in: J Clin Oncol. 2016 Aug 10;34(23):2806.

PMID:
26858332
18.

Macrocytosis as a potential parameter associated with survival after tyrosine kinase inhibitor treatment.

Kloth JSL, Hamberg P, Mendelaar PAJ, Dulfer RR, van der Holt B, Eechoute K, Wiemer EAC, Kruit WHJ, Sleijfer S, Mathijssen RHJ.

Eur J Cancer. 2016 Mar;56:101-106. doi: 10.1016/j.ejca.2015.12.019. Epub 2016 Feb 1.

PMID:
26841094
19.

Melphalan, prednisone, and lenalidomide versus melphalan, prednisone, and thalidomide in untreated multiple myeloma.

Zweegman S, van der Holt B, Mellqvist UH, Salomo M, Bos GM, Levin MD, Visser-Wisselaar H, Hansson M, van der Velden AW, Deenik W, Gruber A, Coenen JL, Plesner T, Klein SK, Tanis BC, Szatkowski DL, Brouwer RE, Westerman M, Leys MR, Sinnige HA, Haukås E, van der Hem KG, Durian MF, Mattijssen EV, van de Donk NW, Stevens-Kroef MJ, Sonneveld P, Waage A.

Blood. 2016 Mar 3;127(9):1109-16. doi: 10.1182/blood-2015-11-679415. Epub 2016 Jan 22.

20.

Identification of Patients with Recurrent Glioblastoma Who May Benefit from Combined Bevacizumab and CCNU Therapy: A Report from the BELOB Trial.

Erdem-Eraslan L, van den Bent MJ, Hoogstrate Y, Naz-Khan H, Stubbs A, van der Spek P, Böttcher R, Gao Y, de Wit M, Taal W, Oosterkamp HM, Walenkamp A, Beerepoot LV, Hanse MC, Buter J, Honkoop AH, van der Holt B, Vernhout RM, Sillevis Smitt PA, Kros JM, French PJ.

Cancer Res. 2016 Feb 1;76(3):525-34. doi: 10.1158/0008-5472.CAN-15-0776. Epub 2016 Jan 13.

21.

Total body irradiation after high-dose cytarabine in mantle cell lymphoma: a comparison of Nordic MCL2, HOVON-45, and European MCL Younger trials.

Hoster E, Geisler CH, Doorduijn J, van der Holt B, Walewski J, Bloehdorn J, Ribrag V, Salles G, Hallek M, Pott C, Szymczyk M, Kolstad A, Laurell A, Räty R, Jerkeman M, Van't Veer M, Kluin-Nelemans JC, Klapper W, Unterhalt M, Dreyling M, Hermine O.

Leukemia. 2016 Jun;30(6):1428-30. doi: 10.1038/leu.2015.322. Epub 2015 Nov 24. No abstract available.

PMID:
26598017
22.

Reduced relapse rate in upfront tandem autologous/reduced-intensity allogeneic transplantation in multiple myeloma only results in borderline non-significant prolongation of progression-free but not overall survival.

Lokhorst HM, van der Holt B, Cornelissen JJ, Kersten MJ, van Oers M, Raymakers R, Minnema MC, Zweegman S, Bos G, Schaap N, Wittebol S, de Weerdt O, Ammerlaan R, Sonneveld P.

Haematologica. 2015 Dec;100(12):e508-10. doi: 10.3324/haematol.2015.128728. Epub 2015 Sep 4. No abstract available.

23.

Prediction of high- and low-risk multiple myeloma based on gene expression and the International Staging System.

Kuiper R, van Duin M, van Vliet MH, Broijl A, van der Holt B, El Jarari L, van Beers EH, Mulligan G, Avet-Loiseau H, Gregory WM, Morgan G, Goldschmidt H, Lokhorst HM, Sonneveld P.

Blood. 2015 Oct 22;126(17):1996-2004. doi: 10.1182/blood-2015-05-644039. Epub 2015 Sep 1.

24.

4β-hydroxycholesterol as an endogenous CYP3A marker in cancer patients treated with taxanes.

de Graan AJ, Sparreboom A, de Bruijn P, de Jonge E, van der Holt B, Wiemer EA, Verweij J, Mathijssen RH, van Schaik RH.

Br J Clin Pharmacol. 2015 Sep;80(3):560-8. doi: 10.1111/bcp.12707. Epub 2015 Aug 12.

25.

Prognostic value and kinetics of circulating endothelial cells in patients with recurrent glioblastoma randomised to bevacizumab plus lomustine, bevacizumab single agent or lomustine single agent. A report from the Dutch Neuro-Oncology Group BELOB trial.

Beije N, Kraan J, Taal W, van der Holt B, Oosterkamp HM, Walenkamp AM, Beerepoot L, Hanse M, van Linde ME, Otten A, Vernhout RM, de Vos FY, Gratama JW, Sleijfer S, van den Bent MJ.

Br J Cancer. 2015 Jul 14;113(2):226-31. doi: 10.1038/bjc.2015.191. Epub 2015 Jun 4.

26.

Clinical Course of Cerebral Venous Thrombosis in Adult Acute Lymphoblastic Leukemia.

Zuurbier SM, Lauw MN, Coutinho JM, Majoie CB, van der Holt B, Cornelissen JJ, Middeldorp S, Biemond BJ, Stam J.

J Stroke Cerebrovasc Dis. 2015 Jul;24(7):1679-84. doi: 10.1016/j.jstrokecerebrovasdis.2015.03.041. Epub 2015 Apr 29.

PMID:
25934140
27.

The impact of bevacizumab on health-related quality of life in patients treated for recurrent glioblastoma: results of the randomised controlled phase 2 BELOB trial.

Dirven L, van den Bent MJ, Bottomley A, van der Meer N, van der Holt B, Vos MJ, Walenkamp AM, Beerepoot LV, Hanse MC, Reijneveld JC, Otten A, de Vos FY, Smits M, Bromberg JE, Taal W, Taphoorn MJ; Dutch Neuro-Oncology Group (LWNO).

Eur J Cancer. 2015 Jul;51(10):1321-30. doi: 10.1016/j.ejca.2015.03.025. Epub 2015 Apr 17.

PMID:
25899986
28.

Neo-adjuvant chemotherapy followed by surgery versus surgery alone in high-risk patients with resectable colorectal liver metastases: the CHARISMA randomized multicenter clinical trial.

Ayez N, van der Stok EP, de Wilt H, Radema SA, van Hillegersberg R, Roumen RM, Vreugdenhil G, Tanis PJ, Punt CJ, Dejong CH, Jansen RL, Verheul HM, de Jong KP, Hospers GA, Klaase JM, Legdeur MC, van Meerten E, Eskens FA, van der Meer N, van der Holt B, Verhoef C, Grünhagen DJ.

BMC Cancer. 2015 Mar 26;15:180. doi: 10.1186/s12885-015-1199-8.

29.

Expression profiling of adult acute lymphoblastic leukemia identifies a BCR-ABL1-like subgroup characterized by high non-response and relapse rates.

Boer JM, Koenders JE, van der Holt B, Exalto C, Sanders MA, Cornelissen JJ, Valk PJ, den Boer ML, Rijneveld AW.

Haematologica. 2015 Jul;100(7):e261-4. doi: 10.3324/haematol.2014.117424. Epub 2015 Mar 13. No abstract available.

30.

Extended follow up of high-dose melphalan and autologous stem cell transplantation after vincristine, doxorubicin, dexamethasone induction in amyloid light chain amyloidosis of the prospective phase II HOVON-41 study by the Dutch-Belgian Co-operative Trial Group for Hematology Oncology.

Hazenberg BP, Croockewit A, van der Holt B, Zweegman S, Bos GM, Delforge M, Raymakers RA, Sonneveld P, Vellenga E, Wijermans PW, von dem Borne PA, van Oers MH, de Weerdt O, Spoelstra FM, Lokhorst HM; Dutch-Belgian Cooperative Trial Group for Hematology Oncology.

Haematologica. 2015 May;100(5):677-82. doi: 10.3324/haematol.2014.119198. Epub 2015 Feb 6.

31.

Stereotactic body radiation therapy for oligometastases to the lung: a phase 2 study.

Nuyttens JJ, van der Voort van Zyp NC, Verhoef C, Maat A, van Klaveren RJ, van der Holt B, Aerts J, Hoogeman M.

Int J Radiat Oncol Biol Phys. 2015 Feb 1;91(2):337-43. doi: 10.1016/j.ijrobp.2014.10.021.

PMID:
25636758
32.

Physiochemical disparity of mismatched HLA class I alloantigens and risk of acute GVHD following HSCT.

Kosmoliaptsis V, Jöris MM, Mallon DH, Lankester AC, von dem Borne PA, Kuball J, Bierings M, Cornelissen JJ, Groenendijk-Sijnke ME, van der Holt B, Bradley JA, Oudshoorn M, van Rood JJ, Taylor CJ, Claas FH.

Bone Marrow Transplant. 2015 Apr;50(4):540-4. doi: 10.1038/bmt.2014.305. Epub 2015 Jan 26.

PMID:
25621806
33.

Diffuse large B cell lymphomas relapsing in the CNS lack oncogenic MYD88 and CD79B mutations.

Kersten MJ, Kraan W, Doorduijn J, Bromberg J, Lam K, Kluin PM, van der Holt BJ, Spaargaren M, Pals ST.

Blood Cancer J. 2014 Dec 12;4:e266. doi: 10.1038/bcj.2014.87. No abstract available.

34.

Experience with outcomes research into the real-world effectiveness of novel therapies in Dutch daily practice from the context of conditional reimbursement.

Gaultney JG, Franken MG, Uyl-de Groot CA, Redekop WK, Huijgens PC, van der Holt B, Lokhorst HM, Sonneveld P.

Health Policy. 2015 Feb;119(2):186-94. doi: 10.1016/j.healthpol.2014.11.010. Epub 2014 Nov 22.

PMID:
25476554
35.

Multi-center randomized open label phase II trial on three rituximab dosing schemes in immune thrombocytopenia patients.

Zwaginga JJ, van der Holt B, Te Boekhorst PA, Biemond BJ, Levin MD, van der Griend R, Brand A, Zweegman S, Pruijt HF, Novotny VM, Vreugdenhil A, de Groot MR, de Weerdt O, van Pampus EC, van Maanen-Lamme TM, Wittebol S, Schipperus MR, Silbermann MH, Huijgens PC, Luten M, Hollestein R, Brakenhoff JA, Schrama JG, Valster FA, Velders GA, Koene HR; Dutch HOVON 64 study group.

Haematologica. 2015 Mar;100(3):e90-2. doi: 10.3324/haematol.2014.110213. Epub 2014 Nov 25. No abstract available.

36.

Phase 2 study of carfilzomib, thalidomide, and dexamethasone as induction/consolidation therapy for newly diagnosed multiple myeloma.

Sonneveld P, Asselbergs E, Zweegman S, van der Holt B, Kersten MJ, Vellenga E, van Marwijk-Kooy M, Broyl A, de Weerdt O, Lonergan S, Palumbo A, Lokhorst H.

Blood. 2015 Jan 15;125(3):449-56. doi: 10.1182/blood-2014-05-576256. Epub 2014 Nov 14.

37.

Rapid induction of single donor chimerism after double umbilical cord blood transplantation preceded by reduced intensity conditioning: results of the HOVON 106 phase II study.

Somers JA, Braakman E, van der Holt B, Petersen EJ, Marijt EW, Huisman C, Sintnicolaas K, Oudshoorn M, Groenendijk-Sijnke ME, Brand A, Cornelissen JJ.

Haematologica. 2014 Nov;99(11):1753-61. doi: 10.3324/haematol.2014.106690. Epub 2014 Aug 8.

38.

Single-agent bevacizumab or lomustine versus a combination of bevacizumab plus lomustine in patients with recurrent glioblastoma (BELOB trial): a randomised controlled phase 2 trial.

Taal W, Oosterkamp HM, Walenkamp AM, Dubbink HJ, Beerepoot LV, Hanse MC, Buter J, Honkoop AH, Boerman D, de Vos FY, Dinjens WN, Enting RH, Taphoorn MJ, van den Berkmortel FW, Jansen RL, Brandsma D, Bromberg JE, van Heuvel I, Vernhout RM, van der Holt B, van den Bent MJ.

Lancet Oncol. 2014 Aug;15(9):943-53. doi: 10.1016/S1470-2045(14)70314-6. Epub 2014 Jul 15.

PMID:
25035291
39.

Combination of international scoring system 3, high lactate dehydrogenase, and t(4;14) and/or del(17p) identifies patients with multiple myeloma (MM) treated with front-line autologous stem-cell transplantation at high risk of early MM progression-related death.

Moreau P, Cavo M, Sonneveld P, Rosinol L, Attal M, Pezzi A, Goldschmidt H, Lahuerta JJ, Marit G, Palumbo A, van der Holt B, Bladé J, Petrucci MT, Neben K, san Miguel J, Patriarca F, Lokhorst H, Zamagni E, Hulin C, Gutierrez N, Facon T, Caillot D, Benboubker L, Harousseau JL, Leleu X, Avet-Loiseau H, Mary JY.

J Clin Oncol. 2014 Jul 10;32(20):2173-80. doi: 10.1200/JCO.2013.53.0329. Epub 2014 Jun 2.

40.

Gene expression profile alone is inadequate in predicting complete response in multiple myeloma.

Amin SB, Yip WK, Minvielle S, Broyl A, Li Y, Hanlon B, Swanson D, Shah PK, Moreau P, van der Holt B, van Duin M, Magrangeas F, Pieter Sonneveld P, Anderson KC, Li C, Avet-Loiseau H, Munshi NC.

Leukemia. 2014 Nov;28(11):2229-34. doi: 10.1038/leu.2014.140. Epub 2014 Apr 15.

41.

Second primary malignancies with lenalidomide therapy for newly diagnosed myeloma: a meta-analysis of individual patient data.

Palumbo A, Bringhen S, Kumar SK, Lupparelli G, Usmani S, Waage A, Larocca A, van der Holt B, Musto P, Offidani M, Petrucci MT, Evangelista A, Zweegman S, Nooka AK, Spencer A, Dimopoulos MA, Hajek R, Cavo M, Richardson P, Lonial S, Ciccone G, Boccadoro M, Anderson K, Barlogie B, Sonneveld P, McCarthy PL.

Lancet Oncol. 2014 Mar;15(3):333-42. doi: 10.1016/S1470-2045(13)70609-0. Epub 2014 Feb 11.

PMID:
24525202
42.

Translating in vitro prediction of cytotoxic T cell alloreactivity to hematopoietic stem cell transplantation outcome.

Jöris MM, Lankester AC, von dem Borne PA, Kuball J, Bierings M, Cornelissen JJ, Sijnke ME, van der Holt B, van Rood JJ, Oudshoorn M, Claas FH.

Transpl Immunol. 2014 Mar;30(2-3):59-64. doi: 10.1016/j.trim.2013.08.006. Epub 2014 Jan 17.

PMID:
24440708
43.

The Effect of Differentiation Grade of Cutaneous Squamous Cell Carcinoma on Excision Margins, Local Recurrence, Metastasis, and Patient Survival: A Retrospective Follow-Up Study.

Brinkman JN, Hajder E, van der Holt B, Den Bakker MA, Hovius SE, Mureau MA.

Ann Plast Surg. 2015 Sep;75(3):323-6. doi: 10.1097/SAP.0000000000000110.

PMID:
24401812
44.

Bortezomib before and after autologous stem cell transplantation overcomes the negative prognostic impact of renal impairment in newly diagnosed multiple myeloma: a subgroup analysis from the HOVON-65/GMMG-HD4 trial.

Scheid C, Sonneveld P, Schmidt-Wolf IG, van der Holt B, el Jarari L, Bertsch U, Salwender H, Zweegman S, Blau IW, Vellenga E, Weisel K, Pfreundschuh M, Jie KS, Neben K, van de Velde H, Duehrsen U, Schaafsma MR, Lindemann W, Kersten MJ, Peter N, Hänel M, Croockewit S, Martin H, Wittebol S, Bos GM, van Marwijk-Kooy M, Wijermans P, Goldschmidt H, Lokhorst HM.

Haematologica. 2014 Jan;99(1):148-54. doi: 10.3324/haematol.2013.087585. Epub 2013 Aug 30.

45.

A pharmacogenetic predictive model for paclitaxel clearance based on the DMET platform.

de Graan AJ, Elens L, Smid M, Martens JW, Sparreboom A, Nieuweboer AJ, Friberg LE, Elbouazzaoui S, Wiemer EA, van der Holt B, Verweij J, van Schaik RH, Mathijssen RH.

Clin Cancer Res. 2013 Sep 15;19(18):5210-7. doi: 10.1158/1078-0432.CCR-13-0487. Epub 2013 Aug 5.

46.

Imatinib discontinuation in chronic phase myeloid leukaemia patients in sustained complete molecular response: a randomised trial of the Dutch-Belgian Cooperative Trial for Haemato-Oncology (HOVON).

Thielen N, van der Holt B, Cornelissen JJ, Verhoef GE, Gussinklo T, Biemond BJ, Daenen SM, Deenik W, van Marwijk Kooy R, Petersen E, Smit WM, Valk PJ, Ossenkoppele GJ, Janssen JJ.

Eur J Cancer. 2013 Oct;49(15):3242-6. doi: 10.1016/j.ejca.2013.06.018. Epub 2013 Jul 19.

47.

Human herpes virus 6 reactivation: important predictor for poor outcome after myeloablative, but not non-myeloablative allo-SCT.

de Pagter PJ, Schuurman R, Keukens L, Schutten M, Cornelissen JJ, van Baarle D, Fries E, Sanders EA, Minnema MC, van der Holt BR, Meijer E, Boelens JJ.

Bone Marrow Transplant. 2013 Nov;48(11):1460-4. doi: 10.1038/bmt.2013.78. Epub 2013 Jun 17.

PMID:
23771003
48.

CYP3A4*22 genotype and systemic exposure affect paclitaxel-induced neurotoxicity.

de Graan AJ, Elens L, Sprowl JA, Sparreboom A, Friberg LE, van der Holt B, de Raaf PJ, de Bruijn P, Engels FK, Eskens FA, Wiemer EA, Verweij J, Mathijssen RH, van Schaik RH.

Clin Cancer Res. 2013 Jun 15;19(12):3316-24. doi: 10.1158/1078-0432.CCR-12-3786. Epub 2013 May 2.

49.

High-dose imatinib versus high-dose imatinib in combination with intermediate-dose cytarabine in patients with first chronic phase myeloid leukemia: a randomized phase III trial of the Dutch-Belgian HOVON study group.

Thielen N, van der Holt B, Verhoef GE, Ammerlaan RA, Sonneveld P, Janssen JJ, Deenik W, Falkenburg JH, Kersten MJ, Sinnige HA, Schipperus M, Schattenberg A, van Marwijk Kooy R, Smit WM, Chu IW, Valk PJ, Ossenkoppele GJ, Cornelissen JJ.

Ann Hematol. 2013 Aug;92(8):1049-56. doi: 10.1007/s00277-013-1730-4. Epub 2013 Apr 10.

PMID:
23572137
50.

Age and organ damage correlate with poor survival in myeloma patients: meta-analysis of 1435 individual patient data from 4 randomized trials.

Bringhen S, Mateos MV, Zweegman S, Larocca A, Falcone AP, Oriol A, Rossi D, Cavalli M, Wijermans P, Ria R, Offidani M, Lahuerta JJ, Liberati AM, Mina R, Callea V, Schaafsma M, Cerrato C, Marasca R, Franceschini L, Evangelista A, Teruel AI, van der Holt B, Montefusco V, Ciccone G, Boccadoro M, San Miguel J, Sonneveld P, Palumbo A.

Haematologica. 2013 Jun;98(6):980-7. doi: 10.3324/haematol.2012.075051. Epub 2013 Feb 26.

Supplemental Content

Loading ...
Support Center